他达拉非
不利影响
医学
子痫前期
剂量
胎儿
产科
头痛
怀孕
麻醉
内科学
外科
勃起功能障碍
遗传学
生物
作者
Fumi Furuhashi,Hiroaki Tanaka,Masanori Kaneda,Shintaro Maki,Masafumi Nii,Takashi Umekawa,Kazuhiro Osato,Yuki Kamimoto,Tomoaki Ikeda
标识
DOI:10.1080/14767058.2018.1487946
摘要
Purpose: The aim of this study is to evaluate the safety of clinical usage of tadalafil in women with preeclampsia.Materials and methods: Maternal, fetal, and neonatal adverse events were closely examined in eight preeclampsia patients receiving tadalafil treatment.Results: There were no maternal adverse events associated with 10 mg/day of tadalafil. Even at 20 mg/day, only grade 1 headaches in two cases and grade 1 palpitation in one case were observed, which resolved spontaneously within 3 days. At a dose of 40 mg/day, there was only one case of grade 1 headache. All these adverse events were grade 1 and spontaneously resolved within 3 days. There were no fetal adverse events. All observed neonatal adverse events were thought to be caused by prematurity and not related to tadalafil.Conclusion: This study shows that tadalafil treatment for preeclampsia is deemed sufficiently tolerable. Although there was a dose-dependent increase in maternal adverse events, all the adverse events were mild and deemed to be safe for the mother and fetus at all dosages.
科研通智能强力驱动
Strongly Powered by AbleSci AI